Lipid Disorders and Their Relevance to Outcomes in Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Cardiovascular disease is the major cause of death in patients with chronic kidney disease (CKD). Cardiovascular disease and many other complications of CKD are mediated by oxidative stress, inflammation, and dyslipidemia. This review provides a concise overview of the nature and mechanisms of CKD-induced lipid disorders and their adverse consequences. Lipid abnormalities in end-stage renal disease are characterized by: (a) reduced serum apoA-1 and high-density lipoprotein (HDL) concentrations, impaired HDL maturation and defective HDL antioxidant, anti-inflammatory and reverse cholesterol transport properties; (b) impaired clearance of very low-density lipoprotein and chylomicrons by the muscle and adipose tissue and of their remnants by the liver leading to hypertriglyceridemia, accumulation of intermediate-density lipoprotein and chylomicron remnants, and (c) oxidative modification of LDL and lipoprotein remnants favored by their structural abnormalities, oxidative stress, and impaired HDL antioxidant activity. Together these abnormalities result in: (a) uptake of oxidized LDL and remnant particles by macrophages and resident cells in the artery wall which along with impaired HDL-mediated reverse cholesterol transport causes foam cell formation and atherosclerosis, (b) production of inflammatory mediators and reactive oxygen species by leukocytes and macrophages in response to stimulation by oxidized LDL and phospholipids leading to intensification of oxidative stress and inflammation, (c) dissemination of oxidative stress by circulating oxidized lipids and lipoproteins via lipid peroxidation chain reaction, (d) heightened injurious effects of oxidative stress and inflammation due to diminished antioxidant, anti-inflammatory and antithrombotic activities of HDL, and finally (e) impaired ability of very low-density lipoprotein and chylomicron to deliver lipid fuel to muscle and adipose tissue contributing to muscle weakness and cachexia which commonly occur in end-stage renal disease patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 1×
“and (g) contribution to cholesterol enrichment and triglyceride depletion of IDL and its maturation to LDL via cholesteryl ester transfer protein (CETP)-mediated exchange of cholesterol ester for triglycerides. This process is referred to as indirect RCT as it employs LDL to dispose a portion of HDL’s cholesterol carg…”
BackgroundThe elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia
Himmelfarb, J., Stenvinkel, P., Ikizler, T. A., & Hakim, R. M. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00600.x · Cited by 1,179 · cited 1×
“Atherosclerosis and cardiovascular disease as well as many other complication of CKD are primarily driven by oxidative stress, inflammation, and lipid disorders [”
Background
Cited by
Ruiz, S., Pergola, P. E., Zager, R. A., & Vaziri, N. D. (2013) · Kidney International · doi:10.1038/ki.2012.439 · Cited by 718
Self-citationChronic Kidney Disease as Oxidative Stress- and Inflammatory-Mediated Cardiovascular Disease
Podkowińska, A., & Formanowicz, D. (2020) · Antioxidants · doi:10.3390/antiox9080752 · Cited by 356
Lipid (per) oxidation in mitochondria: an emerging target in the ageing process?
Ademowo, O. S., Dias, H. K. I., Burton, D. G. A., & Griffiths, H. R. (2017) · Biogerontology · doi:10.1007/s10522-017-9710-z · Cited by 184
Serum Metabolite Concentrations and Decreased GFR in the General Population
Goek, O.-N., Döring, A., Gieger, C., Heier, M., Koenig, W., Prehn, C., Römisch-Margl, W., Wang-Sattler, R., Illig, T., Suhre, K., et al. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.01.014 · Cited by 121
Serum adropin level in patients with stable coronary artery disease
Zhao, L.-P., Xu, W.-T., Wang, L., You, T., Chan, S.-P., Zhao, X., & Yang, X.-J. (2015) · Heart Lung and Circulation · doi:10.1016/j.hlc.2015.03.008 · Cited by 46
“Renal dysfunction could induce oxidative stress, lipids metabolism disorders and inflammatory activation, thus resulting in the progression of atherosclerosis [27,28].”
Background
Metadata
- Authors
- Vaziri, N. D., & Norris, K.
- Venue
- Blood Purification
- Publisher
- S. Karger AG
- Published
- 2011
- Volume
- 31
- Issue
- 1-3
- Pages
- 189-196
- ISSN
- 0253-5068 (ISSN-L)
- 1421-9735
- OpenAlex
- W1978979590
- Cited by
- 155
- References
- 3
- FWCI
- 14.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lipid Disorders and Their Relevance to Outcomes in Chronic Kidney Disease. https://app.cochat.ai/papers/10.1159/000321845
- The paper
- Vaziri, N. D., & Norris, K. (2011). Lipid Disorders and Their Relevance to Outcomes in Chronic Kidney Disease. Blood Purification. https://doi.org/10.1159/000321845
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.